-transparent.png){kind=logo}
One hundred and forty-seven fully and partially evaluable patients with advanced measurable malignancies of the genitourinary and gynecologic organs were given cis-dichlorodiammineplatinum(II) at a dose of 75 mg/m2 iv every 3 weeks. Thirty-six patients with testicular neoplasms were studied; five complete responses (13.9%) and seven partial responses (PR) (19.4%) were noted. Thirty-seven patients with ovarian adenocarcinoma were evaluated; five PRs (13.5%) were seen. One complete response (11.1%) and two PRs (22.2%) were obtained among nine patients with urinary bladder cancer. Four PRs (19.0%) were seen among a group of 21 patients with advanced prostate cancer. One PR (4.8%) was noted among 21 patients with renal cell cancer and no responses were seen in eight patients with cervical cancer. There was a highly statistically significant (P less than 0.001) survival advantage for the responding testicular tumor patients. Toxicity was similar to that previously reported, with gastrointestinal side effects and nephrotoxicity most commonly seen. Prospective and sequential analysis of renal function provided strong evidence for cumulative nephrotoxicity in these patients given bolus injections of cis-dichlorodiammineplatinum(II) without prehydration or treatment with fuosemide or mannitol.
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
January 1979,
Cancer treatment reports,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
January 1979,
Cancer treatment reports,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
January 1979,
Cancer treatment reports,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
March 1979,
Cancer treatment reports,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
January 1994,
Cancer investigation,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
January 1994,
Investigational new drugs,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
February 1982,
Cancer treatment reports,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
February 1990,
Investigational new drugs,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
August 1979,
Cancer treatment reports,
A H Rossof, and
R W Talley, and
R Stephens, and
T Thigpen, and
M K Samson, and
C Groppe, and
H J Eyre, and
R Fisher
January 1979,
Cancer treatment reports,
